The metaverse is still in its nascent stages, and the Chinese government is already increasingly focused on its development and regulation. At the March 2022 “Two Sessions” (两会), a term given to the back-to-back annual...more
5/12/2022
/ Algorithms ,
Anti-Corruption ,
Anti-Money Laundering ,
Artificial Intelligence ,
China ,
Corporate Counsel ,
Cryptocurrency ,
Drug Trafficking ,
Metaverse ,
Political Parties ,
Popular ,
Regulatory Requirements ,
Tax Evasion ,
Terrorism Funding ,
Virtual Reality
On November 1, 2021, the Personal Information Protection Law of the People’s Republic of China (the “PRC”) (the “Personal Information Protection Law”) went into effect, two months after the Data Security Law of the PRC (the...more
2/4/2022
/ Anonymization ,
China ,
Consent ,
Cybersecurity ,
Data Collection ,
Data Privacy ,
Data Processing Rules ,
Data Processors ,
Data Protection ,
Data Security ,
De-Identification ,
Information Security ,
International Data Transfers ,
Multinationals ,
Penalties ,
Personal Information ,
Personal Information Protection Law (PIPL) ,
Personally Identifiable Information ,
Privacy Laws
On July 1, 2019, the Administrative Regulations on Human Genetic Resources (人类遗传资源管理条例) (the “Regulations”) issued by the State Council of the People’s Republic of China (the “PRC”) came into effect. On October 17, 2020, the...more
1/28/2022
/ China ,
Clinical Trials ,
Collaboration ,
Data Collection ,
Data Preservation ,
Filing Requirements ,
Foreign Entities ,
Human Genes ,
Life Sciences ,
Penalties ,
Research and Development
In response to recent data security concerns arising from overseas listings of Chinese internet companies operating in the People’s Republic of China (the “PRC”), the Cyberspace Administration of China (the “CAC”) has issued...more
Since the introduction of a new listing regime on 30 April 2018 that enables the listing of pre-revenue Biotech Companies on the Main Board of the Hong Kong Stock Exchange (the “Exchange”), a total of 16 of these listings...more
In response to the outbreak of a pneumonia-like disease caused by coronavirus (COVID-19), Chinese regulatory authorities adopted a few emergency measures under certain “Special Review and Approval Procedures” to fast-track...more
3/9/2020
/ China ,
Coronavirus/COVID-19 ,
Drug Approvals ,
Health and Safety ,
Infectious Diseases ,
Investigational New Drug Application (IND) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Amendments ,
Public Health ,
Vaccinations